Maddi Hebebrand, MC, Associate Editor

Delgocitinib showed consistent efficacy in atopic, irritant, allergic, and hyperkeratotic forms of chronic hand eczema in pooled trial data.

The investigational extended-release tablet maintained therapeutic plasma levels while avoiding peaks linked to cardiovascular risk.

The approval represents the sixth FDA authorization for roflumilast since 2022.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Quality of life improvements paralleled clinical efficacy in the CUPID studies of dupilumab.

Trial data show up to 30% of patients achieved complete response and 70% demonstrated some benefit from treatment.

Disc Medicine filed an NDA for bitopertin to treat erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) in patients ≥12 years.

The vaccine is designed to stimulate T cell responses against IDO1- and PD-L1–positive cells within the tumor microenvironment.

ORKA-001 builds on the proven success of existing IL-23 inhibitors used in psoriasis treatment.

While VELA-1 achieved statistical significance under all analyses, VELA-2 narrowly missed its composite primary endpoint due to higher-than-expected placebo outcomes.

Fewer than 20% of eligible patients currently receive injectable therapies, highlighting the need for oral alternatives.

Test your knowledge of key words and terms associated with dermatology news from the last month.

Both treatments were well tolerated, with only mild, self-limiting adverse effects reported.

Dermatology Times is recapping our exclusive expert interviews from the month of September.

Many HS patients still require more aggressive or advanced treatments due to incomplete response to current options.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Bambusa Therapeutics reveals promising phase I trial results for BBT001, targeting atopic dermatitis with dual-action bispecific antibodies.

Virginia Sybert, MD, emphasizes the importance of judicious genetic testing in pediatric dermatology, advocating for collaboration to enhance patient care.

This episode explores the controversy and lack of clear diagnostic criteria for TSW.

Bristol Myers Squibb expands direct-to-patient pricing for deucravacitinib and apixaban, enhancing access and affordability for patients in need.

By targeting IL-13, APG777 may allow for less frequent dosing compared to existing biologics.

Explore groundbreaking research and insights from the EADV Congress 2025, highlighting advancements in dermatology treatments and patient care.

Rebecca Smith, MD, recently led a Dermatology Times Case-Based Roundtable event on complex cases in atopic dermatitis.

Evidence presented at EADV supports upadacitinib’s long-term use in atopic dermatitis and other inflammatory conditions.

Patients switched from placebo to remibrutinib at week 24 showed similar reductions in autoantibodies by week 52.

At week 16, up to 61% mean EASI reduction was observed in high-dose patients versus 31% in placebo.

Treatment with APG777 led to a significant 71.0% reduction in EASI scores from baseline to week 16, compared to a 33.8% reduction with placebo, according to data presented at EADV 2025.